The Food and Drug Administration approved an oral therapy for advanced multiple myeloma developed by Bristol Myers Squibb. The agent, iberdomide, will be marketed under the brand name Zenbexus. The public reporting indicates this approval represents both a therapeutic and regulatory milestone for the blood cancer field.
The accessible portion of the source material states that Zenbexus is approved for use in combination with other agents for patients who have already received prior therapy, but full clinical details available in the original report are limited by a subscription barrier.
According to the report, the approved use of Zenbexus is in combination with Darzalex (daratumumab) and dexamethasone. The indication given in the available text specifies treatment of patients with multiple myeloma who have received at least one prior line of therapy.
The source did not provide further specifics on dosing schedules, duration of therapy, contraindications, recommended monitoring, or detailed safety information in the publicly available excerpt. Those clinical and prescribing details were not reported in the accessible portion of the article.
The approval is notable for two regulatory-first elements reported in the article. First, Zenbexus is described as the debut of a novel class of drugs for multiple myeloma, making Bristol the first company to bring this new class to market for this indication.
Second, the article states that Zenbexus is the first drug cleared by U.S. regulators using a more sensitive measure of remission. The accessible text does not define the specific assay or metric used, nor does it provide the clinical data that supported reliance on that measure. The report therefore confirms the regulatory novelty but does not include the technical or evidentiary details behind the claim in the excerpt provided.
Cristian Massacesi, Bristol’s chief medical officer, is quoted in the article saying that with the Zenbexus approval, Bristol is the first company to introduce this novel drug class to patients with multiple myeloma and that the approval opens avenues for additional combination regimens. This quote appears in the portion of the story that was available without subscription.
No additional commentary from outside experts, patient advocates, or independent regulators was available in the publicly accessible portion of the source text.
Substantial portions of the original STAT article were behind the STAT+ subscription paywall. The accessible excerpt conveyed the core regulatory announcement and a company comment but did not report key clinical information that clinicians and decision-makers typically need, including:
Because those details were not present in the provided source text, they are not described here. The original STAT report indicates that the remainder of the story and in-depth coverage are available only to STAT+ subscribers.
This coverage was published by STAT and written by Adam Feuerstein. The article date shown in the available content is Aug. 14, 2026. The report identified the drug as iberdomide with the brand name Zenbexus and noted its approval in combination with daratumumab and dexamethasone for patients with multiple myeloma after at least one prior therapy.
For clinicians seeking the full regulatory rationale, trial data, and prescribing information, the accessible excerpt indicates those details were part of the subscriber-only portion of the STAT piece and therefore were not reported in the provided source material.
If you would like, I can help locate FDA documents, the Bristol Myers Squibb press release, or peer-reviewed trial reports for this approval if those sources are available and you want a more complete clinical and regulatory summary. The current rewrite includes only facts stated in the provided source excerpt.